<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Iran Med</journal-id><journal-id journal-id-type="iso-abbrev">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">Arch Iran Med</journal-id><journal-id journal-id-type="publisher-id">AIM</journal-id><journal-title-group><journal-title>Archives of Iranian Medicine</journal-title></journal-title-group><issn pub-type="ppub">1029-2977</issn><issn pub-type="epub">1735-3947</issn><issn-l>1029-2977</issn-l><publisher><publisher-name>Academy of Medical Sciences of I.R. Iran</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40001324</article-id><article-id pub-id-type="pmc">PMC11862393</article-id><article-id pub-id-type="doi">10.34172/aim.27746</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prognostic Features for Overall Survival in Male Diabetic Patients Undergoing Hemodialysis Using Elastic Net Penalized Cox Regression; A Machine Learning Approach</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1391-1968</contrib-id><name><surname>Sharifi</surname><given-names>Mehrdad</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9483-8848</contrib-id><name><surname>Mousavi-Roknabadi</surname><given-names>Razieh Sadat</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref><xref rid="A03" ref-type="aff">
<sup>3</sup>
</xref><xref rid="A04" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4203-3957</contrib-id><name><surname>Ebrahimi</surname><given-names>Vahid</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/software/">Software</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A02" ref-type="aff">
<sup>2</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2163-8834</contrib-id><name><surname>Sadegh</surname><given-names>Robab</given-names></name><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0469-5527</contrib-id><name><surname>Dehbozorgi</surname><given-names>Afsaneh</given-names></name><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hosseini-Marvast</surname><given-names>Seyed Rouhollah</given-names></name><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="A01" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mokdad</surname><given-names>Mojtaba</given-names></name><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="A05" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="A01">
<sup>1</sup>Emergency Medicine Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Emergency Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</aff><aff id="A02">
<sup>2</sup>Health System Research, Vice-Chancellor of Treatment, Shiraz University of Medical Sciences, Shiraz, Iran Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran</aff><aff id="A03">
<sup>3</sup>Department of Community Medicine, School of Medicine Shiraz University of Medical Sciences, Shiraz, Iran</aff><aff id="A04">
<sup>4</sup>Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</aff><aff id="A05">
<sup>5</sup>Gomel State Medical University, Gomel, Belarus</aff><author-notes><corresp id="COR1">
<label>*</label><bold>Corresponding Author:</bold> Vahid Ebrahimi, Email: <email>biostat.ebrahimiv@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>1</month><year>2025</year></pub-date><volume>28</volume><issue>1</issue><fpage>9</fpage><lpage>17</lpage><history><date date-type="received"><day>29</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Author(s).</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="https://journalaim.com">https://journalaim.com</self-uri><abstract><sec id="sa1"><title>Background:</title><p> Diabetics constitute a significant percentage of hemodialysis (HD) patients with higher mortality, especially among male patients. A machine learning algorithm was used to optimize the prediction of time to death in male diabetic hemodialysis (MDHD) patients. </p></sec><sec id="sa2"><title>Methods:</title><p> This multicenter retrospective study was conducted on adult MDHD patients (2011-2019) from 34 HD centers affiliated with Shiraz University of Medical Sciences. As a special type of machine learning approach, an elastic net penalized Cox proportional hazards (EN-Cox) regression was used to optimize a predictive regression model of time to death. To maximize the generalizability and simplicity of the final model, the backward elimination method was used to reduce the estimated predictive model to its core covariates. </p></sec><sec id="sa3"><title>Results:</title><p> Out of 442 patients, 308 eligible cases were used in the final analysis. Their death proportion was estimated to be 28.2%. The estimated overall one-, two-, three-, and eight-year survival rates were 87.6%, 74.4%, 67.2%, and 53.9%, respectively. The EN-Cox regression model retained 14 (out of 35) candidate predictors of death. Five variables were excluded through backward elimination technique in the next step. Only 6 of the remaining 9 variables were statistically significant at the level of 5%. Body mass index (BMI)&#x0003c;25 kg/m<sup>2</sup> (HR=2.75, <italic toggle="yes">P</italic>&#x0003c;0.001), vascular access type (HR=2.60, <italic toggle="yes">P</italic>&#x0003c;0.001), systolic blood pressure (1.02, <italic toggle="yes">P</italic>=0.003), hemoglobin (11&#x02264;Hb&#x02264;12.5 g/dL: HR=3.00, <italic toggle="yes">P</italic>=0.028 and Hb&#x0003c;11 g/dL: HR=2.95, <italic toggle="yes">P</italic>=0.021), dialysis duration in each session&#x02265;4hour (HR=2.95, <italic toggle="yes">P</italic>&#x0003c;0.001), and serum high-density lipoprotein cholesterol (HDL-C) (HR=1.02, <italic toggle="yes">P</italic>=0.022) had significant effects on the overall survival (OS) time. </p></sec><sec id="sa4"><title>Conclusion:</title><p> Anemia, hypotension, hyperkalemia, having central venous catheter (CVC) as vascular access, a longer dialysis duration in each session, lower BMI and HDL-C were associated with lower mortality in MDHD patients.</p></sec></abstract><kwd-group><kwd>Diabetic</kwd><kwd>Elastic net</kwd><kwd>Hemodialysis</kwd><kwd>Machine learning</kwd><kwd>Male</kwd></kwd-group></article-meta><notes><p>
<bold>Cite this article as:</bold> Sharifi M, Mousavi-Roknabadi RS, Ebrahimi V, Sadegh R, Dehbozorgi A, et al. Prognostic features for overall survival in male diabetic patients undergoing hemodialysis using elastic net penalized cox regression; a machine learning approach. Arch Iran Med. 2025;28(1):9-17. doi: 10.34172/aim.27746</p></notes></front><body><sec sec-type="introduction" id="s1"><title>Introduction</title><p> Diabetes mellitus (DM) accelerates the reduction of glomerular filtration which leads to the development of end-stage renal disease (ESRD).<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> The administration of renal replacement therapy (RRT), which removes toxic substances and extra fluids, is a life-saving treatment in patients with ESRD.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> RRT includes hemodialysis (HD), peritoneal dialysis (PD),<sup><xref rid="R3" ref-type="bibr">3</xref>-<xref rid="R5" ref-type="bibr">5</xref></sup> and kidney transplantation (KT).<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Among RRTs, HD is the most popular treatment, followed by PD and KT.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Previous studies have shown that the survival of patients undergoing HD is affected by several factors some of which are modifiable<sup><xref rid="R8" ref-type="bibr">8</xref></sup> including serum albumin concentrations,<sup><xref rid="R9" ref-type="bibr">9</xref></sup> body fat tissue,<sup><xref rid="R10" ref-type="bibr">10</xref></sup> hemoglobin A1C (HbA1C) levels,<sup><xref rid="R11" ref-type="bibr">11</xref></sup> serum lipids,<sup><xref rid="R12" ref-type="bibr">12</xref></sup> serum ferritin levels,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and white blood cell (WBC) and red blood cell (RBC) counts.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p><p> Gender has been acknowledged as one of the strongest prognostic factors for survival of patients undergoing HD. The progression of chronic kidney disease (CKD) is different in genders due to various factors. Several researches have reported that the male gender (especially men with diabetic nephropathy) is at higher risk of progression to ESRD and death.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> Although the exact biological mechanisms for the faster decrease of the estimated glomerular filtration rate (eGFR) in men are unknown, previous studies have suggested various theories.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> For instance, an unhealthier lifestyle, the detrimental effects of testosterone, lack of estrogen&#x02019;s protective effects in men, sex differences in the metabolism of nitrogen oxide, oxidative stress, and the actions of sex steroids can be mentioned in this regard.<sup><xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R19" ref-type="bibr">19</xref></sup></p><p> In the study of survival time data, larger sample sizes and more events of interest are frequently preferred. Previous simulation studies have shown that fitting survival models with multiple covariates using ordinary regression procedures with small sample data may lead to bias in the estimation of the coefficients since the outcome events per candidate covariate (OEPCC) are too few. This can lead to unstable predictions and the regression models may perform poorly on new datasets.<sup><xref rid="R20" ref-type="bibr">20</xref>-<xref rid="R22" ref-type="bibr">22</xref></sup> Among the different techniques to model the survival time data, the Cox proportional hazards (PH) regression model is the best known procedure because it has fewer assumptions.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> As a rule of thumb, a minimum of five to twenty OEPCC are needed for reliable results in the Cox PH model.<sup><xref rid="R20" ref-type="bibr">20</xref>-<xref rid="R22" ref-type="bibr">22</xref></sup> However, when the sample size is relatively small, if the number of the candidate covariates is relatively large, the number of the OEPCC tends to be smaller than expected and using ordinary survival time methods can be misleading.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> In this situation, using the elastic net penalized Cox (EN-Cox) regression model, as a special type of machine learning approach, is the best option.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> The elastic net regressions solve this problem by adding a penalty term to the log-likelihood function (including the unknown parameters of the model) which is used to estimate the model parameters.</p><p> In general, narrowing down a large set of covariates to a smaller one can improve our understanding of the most significant predictors of death. To select the variables, machine learning procedures such as the elastic net and the least absolute shrinkage and selection operator (LASSO) regressions can be used.<sup><xref rid="R25" ref-type="bibr">25</xref></sup></p><p> Diabetic patients constitute a significant percentage of HD patients and have higher mortality, especially male patients,<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> than nondiabetic patients.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Therefore, the current study aimed to derive a parsimonious model for predicting overall survival (OS) among male diabetic HD (MDHD) patients and to determine its associated factors. In the present study, as a special type of machine learning method, the EN-Cox regression model (which has not been used for MDHD patients&#x02019; data so far) was applied to optimize the prediction of time to death.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><sec sec-type="subsection" id="s2-1"><title> Study Design and Setting</title><p> This multicenter retrospective cohort study was conducted on all MDHD patients who referred to 34 hospitals affiliated with Shiraz University of Medical Sciences (SUMS) from June 29, 2011 to March 1, 2019. The inclusion criteria were all MDHD patients with the age of&#x02005;&#x02265;&#x02005;18 years with at least 4 months since their first HD. Patients with high missing data rates due to unknown last status were excluded from the study. The patients&#x02019; demographic characteristics, laboratory and clinical findings, and outcomes were extracted from the Special Diseases Database of SUMS.</p></sec><sec sec-type="subsection" id="s2-2"><title> Statistical Analysis</title><p> The time interval from four months after the first HD to the end of follow-up was considered as the censored time if the desired event (i.e. death) did not happen during it. The patients&#x02019; survival probability was estimated using the non-parametric Kaplan-Meier (KM) method and the various groups were compared via the log-rank test.<sup><xref rid="R24" ref-type="bibr">24</xref></sup></p></sec><sec sec-type="subsection" id="s2-3"><title> The Elastic Net Penalized Cox Model</title><p> When the sample size is relatively large, the model parameters can be accurately estimated via the conventional maximum likelihood method.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> In most cases, however, the sample size is not large enough to achieve unique and reliable coefficient estimates. Here, stable results can be generated by using the penalized version of the objective (or log-likelihood) function.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> As special types of machine learning methods, the LASSO and Ridge models are two different types of penalization techniques that shrink the regression coefficient estimates towards zero to achieve unique estimates.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> (See <xref rid="Suppl2" ref-type="supplementary-material">Supplementary file 2</xref> for more information) Unlike the Ridge model which always creates a prognostic regression model that includes all the candidate covariates, the LASSO algorithm performs variable selection, as well. In fact, the LASSO technique results in a sparse model, i.e. a regression model that includes only a small subset of the covariates.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p><p> As a machine learning approach, the elastic net penalized model is a combination of the LASSO and Ridge regression models<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> and its log-likelihood function can be formulated as follows:</p><disp-formula id="DF1">
<label>(1)</label>
<mml:math id="m1" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>l</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mi>L</mml:mi><mml:mo>+</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:mfenced><mml:mrow><mml:mfenced><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mo>+</mml:mo><mml:mi>w</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mi>L</mml:mi><mml:mi>A</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mi>O</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:math>
</disp-formula><p> Where <italic toggle="yes">log</italic> L is an unpenalized log-likelihood function, while <italic toggle="yes">w</italic> and &#x1d706; are regularization parameters which are data-dependent and <italic toggle="yes">a priori</italic> values cannot be attributed to them. The LASSO (<italic toggle="yes">w</italic>=&#x02005;1) and Ridge (<italic toggle="yes">w</italic>=&#x02005;0) models are specific cases of the elastic net model.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup></p><p> The main challenge is to specify these regularization parameters for which the cross-validated log-likelihood function of the fitted model is maximum. The 5-fold cross-validation method was applied. To perform cross-validation, the dataset was randomly divided into five equal folds. First, one fold was held out and a separate regression model was trained on all the other folds. Then, the trained model was tested on the held-out fold and the prediction error was calculated. After repeating this process and using all the five folds as the validation sets, the average of the five calculated errors was called the &#x02018;cross-validation error&#x02019;.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p><p> When the OEPCC are too few, instead of the conventional Cox-adjusted PH model, an alternative penalized regression can be utilized. In this study, an EN-Cox algorithm was used to model time to death in MDHD patients. Similar to the LASSO regression, the elastic-net algorithm performs variable selection by setting some model parameter estimates exactly to zero. The variables selected by the EN-Cox method were then entered into an unpenalized Cox model to specify a baseline for comparison during model development. In order to reduce the number of variables in the baseline model and to obtain a parsimonious one, the backward elimination procedure was used.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> All the statistical analyses were done using the &#x0201c;<italic toggle="yes">survival</italic>&#x0201d; and &#x0201c;<italic toggle="yes">glmnet</italic>&#x0201d; packages in the R statistical software (version: 3.6.3).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p> Out of the 422 adult MDHD patients assessed for eligibility, 114 (27%) patients did not meet the inclusion criteria. Hence, the analyses were restricted to 308 adult MDHD patients (<xref rid="F1" ref-type="fig">Figure 1</xref>). With the mean (&#x02005;&#x000b1;&#x02005;SD) age of 64.2 (12.9) (range: 27&#x02012;94) years and the body mass index (BMI) of 24.7 (2.5) (range: 14&#x02013;36) kg/m<sup>2</sup>, the empirical mortality rate was 28.2%. The details of the baseline demographic characteristics as well as the findings of the clinical and laboratory tests are shown in <xref rid="T1" ref-type="table">Table 1</xref>.</p><fig position="float" id="F1"><label>Figure 1</label><graphic xlink:href="aim-28-9-g001" position="float"/><statement><p>
Data Structure of the Adult Male Diabetic Hemodialysis Patients Utilized in the Analyses</p></statement></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Characteristics of the Adult Male Diabetic Hemodialysis Patients in the Elastic Net Penalized Cox-Adjusted Regression Analysis
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="2" colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;">
<bold>Factors</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Non-survivors</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Survivors</bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Mean (&#x000b1;SD)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>Mean (&#x000b1;SD)</bold>
</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1">Age (y)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">63.9 (21.8)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">65.0 (31.2)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Pre-dialysis weight (kg)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">70.0 (10.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">65.8 (9.9)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="vertical-align:middle;" rowspan="1">Post-dialysis weight (kg)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">86.1 (10.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">64.4 (9.9)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Dry weight (kg)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">67.8 (11.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">64.1 (10.2)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">FBS (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">119.1 (55.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">121.8 (55.5)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Sodium (mEq/L)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">138.8 (3.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">138.8 (4.8)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Calcium (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8.6 (0.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">8.5 (0.8)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Potassium (mEq/L)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5.0 (0.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5.1 (0.8)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="vertical-align:middle;" rowspan="1">Phosphate (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4.9 (1.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">5.1 (0.8)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">DBP (mm Hg)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">78.9 (8.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">77.8 (9.4)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">SBP (mm Hg)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">134.7 (17.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">131.8 (17.5)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Uric acid (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6.4 (1.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6.4 (1.4)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">WBC (10<sup>6</sup>/&#x003bc;L)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14.7 (20.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">12.3 (15.7)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Iron (&#x003bc;g/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">107.9 (112.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">116.1 (123.3)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">MCHC (g/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">31.1 (1.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">30.8 (1.6)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Ferritin (&#x003bc;g/L)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">352.4 (277.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">318.8 (239.5)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Albumin (g/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.7 (0.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.8 (0.6)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Post-dialysis serum creatinine (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.8 (.12)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.9 (1.3)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Pre-dialysis serum creatinine (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6.6 (2.7)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">6.8 (2.9)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Pre-dialysis BUN (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">54.7 (16.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">55.0 (14.5)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Post-dialysis BUN (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18.2 (7.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18.0 (6.1)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Cholesterol (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">127.8 (30.2)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">127.4 (27.3)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">LDL (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">74.6 (35.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">80.6 (64.7)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Triglyceride (mg/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">78.8 (16.8)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">80.6 (20.8)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Adequacy of dialysis (Kt/V<sub>urea</sub>)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.3 (0.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.3 (0.4)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">UF (mL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.1 (0.8))</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.89 (0.9)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">AST (U/L)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">18.3 (9.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">17.4 (7.4)</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">ALT (U/L)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16.8 (11.6)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">16.0 (9.0)</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">ALKPH (Alkaline phosphatase) (IU/L)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">335.2 (260.4)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">311.6 (205.8)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Dialysis duration per session (h)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x02265;&#x02005;4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4.0 (0.1)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">4.1 (0.1)</td></tr><tr><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.8 (0.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">3.6 (0.5)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">BMI (Body mass index) (kg/m<sup>2</sup>)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;25</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23.6 (1.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">23.4 (1.5</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x02265;&#x02005;25</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27.2 (2.3)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">27.5 (2.8)</td></tr><tr><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">Hemoglobin (g/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;11</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9.5 (1.0)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">9.2 (1.2)</td></tr><tr><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11-12.5</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11.6 (0.5)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11.6 (0.4)</td></tr><tr><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003e;&#x02005;12.5</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">13.5 (0.9)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">14.7 (1.2)</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Vascular access type<sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">AVF</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">89 (29)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">19 (6)</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">CVC</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">132 (43)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">68 (22)</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Type of membrane flux<sup>a</sup></td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">Low Flux</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">98 (29)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">37 (12)</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">High Flux</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">132 (43)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">50 (16)</td></tr></tbody></table><table-wrap-foot><fn><p> AVF, Arteriovenous fistula; BUN, Blood urea nitrogen; CVC, Central venous catheter; HDL-C, High-density lipoprotein cholesterol; LDL, Low-density lipoprotein; MCHC, Mean corpuscular hemoglobin concentration; SD, Standard deviation; FBS, Fasting blood sugar; DBP, Diastolic blood pressure; SBP, Systolic blood pressure; WBC, White blood cell; UF, Ultrafiltration volume.</p><p>
<sup>a</sup> Data are expressed as number (%).</p></fn></table-wrap-foot></table-wrap><p> The KM curves for the survival function are presented in <xref rid="F2" ref-type="fig">Figures 2</xref> and <xref rid="F3" ref-type="fig">3</xref>. The curves detail the time to death in this study. The x-axes represent the time elapsed (in months) from the start (4 months after the first HD) and the y-axes are the survival probabilities. By definition, the median survival is the time at which half of the patients have experienced the desired event (i.e. death). When survival probability exceeds 50% at the longest survival time points, the median survival time cannot be calculated. Hence, in this situation, the restricted mean survival time can be used as an alternative to the median survival time.<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> Using the KM plot (<xref rid="F2" ref-type="fig">Figure 2</xref>), the median survival time remained undefined as more than 50% of patients were still alive. Therefore, the restricted mean survival time was calculated to be 61.5 months (95% CI: 56.3&#x02012;66.6). In addition, as <xref rid="F2" ref-type="fig">Figure 2</xref> shows, 11.4% of the patients experienced the death event by the end of the 1<sup>st</sup> year, while 16.9% of them died from that point to the end of the 8-year period of dialysis data collection. The estimated overall one-, two-, three-, and eight-year survival rates (95% CI) in the MDHD patients were 87.6% (83.2&#x02012;90.9%), 74.4% (68.4&#x02012;79.4%), 67.2% (60.3&#x02012;73.1%), and 53.9% (50.0&#x02012;62.0%), respectively.</p><fig position="float" id="F2"><label>Figure 2</label><graphic xlink:href="aim-28-9-g002" position="float"/><statement><p>
Overall Non-parametric Kaplan-Meier (KM) Survival Estimate for the Male Diabetic Hemodialysis Population (solid line) and its corresponding 95% Confidence Interval (dashed line). The total analysis time at risk and under observation was 8487 days</p></statement></fig><fig position="float" id="F3"><label>Figure 3</label><graphic xlink:href="aim-28-9-g003" position="float"/><statement><p>
(a) BMI:&#x02005;&#x0003c;&#x02005;25 kg/m<sup>2</sup> (solid line) and&#x02005;&#x02265;&#x02005;25 kg/m<sup>2</sup> (dashed line) [Cox regression-based test: LR Chi-squared statistics&#x02005;=&#x02005;8.68, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.003]; (b) Initial vascular access type: AVF (solid line) and CVC (dashed line) [Cox regression-based test: LR Chi-squared statistics&#x02005;=&#x02005;5.67, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.017]; (c) Dialysis duration per session (hour):&#x02005;&#x0003c;&#x02005;4 hour (solid line) and&#x02005;&#x02265;&#x02005;4 hour (dashed line) [Cox regression-based test: LR Chi-squared statistics&#x02005;=&#x02005;3.31, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.069]; (d) Hemoglobin:&#x02005;&#x0003c;&#x02005;11 g/dL (solid line), 11-12.5 g/dL (dashed line) and&#x02005;&#x0003e;&#x02005;12.5 g/dL (dotted line) [Cox regression-based test: LR Chi-squared statistics&#x02005;=&#x02005;6.90, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.032]</p></statement></fig><p> The results of the non-parametric log-rank test showed that the MDHD patients with BMI&#x02005;&#x02265;&#x02005;25 kg/m<sup>2</sup> (<italic toggle="yes">&#x003c7;</italic><sup>2</sup> =&#x02005;8.68, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.003), hemoglobin (Hb) level&#x02005;&#x0003e;&#x02005;12.5 g/dL (<italic toggle="yes">&#x003c7;</italic><sup>2</sup> =&#x02005;6.90, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.032), arteriovenous fistula (AVF) as vascular access (<italic toggle="yes">&#x003c7;</italic><sup>2</sup> =&#x02005;5.67, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.017), and dialysis duration less than four hours per session (<italic toggle="yes">&#x003c7;</italic><sup>2</sup> =&#x02005;3.31, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.069) were associated with higher levels of OS compared with the other patients (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p><sec sec-type="subsection" id="s3-1"><title> Results of the Elastic Net Penalized Cox Regression </title><p> As a machine learning method, the EN-Cox regression model was used to model the time-to-death data. This penalized model was fitted using a combination of optimized &#x1d706; values for the LASSO (<italic toggle="yes">w</italic>=&#x02005;1) and Ridge (<italic toggle="yes">w</italic>=&#x02005;0) regressions. The weighting (<italic toggle="yes">w</italic>) and regularization (&#x1d706;) parameters were optimized by averaging over five repetitions of five-fold cross-validation to minimize the mean-squared error (MSE) (<italic toggle="yes">w</italic><sub>optimal&#x02005;</sub>=&#x02005;0.6 and &#x1d706;<sub>optimal&#x02005;</sub>=&#x02005;0.0448) (Figure S1). The EN-Cox regression model retained 14 (out of 35) candidate predictors of death. The estimated shrunken coefficients for all the retained factors are presented in Table S1. These estimated model parameters may be interpreted in the same way as unpenalized regression parameters, whereby higher values indicate a greater magnitude of effect. Using the EN-Cox model, the highest magnitude effects were the initial vascular access type (coefficient&#x02005;=&#x02005;0.52096), dialysis duration per session (coefficient&#x02005;=&#x02005;0.49019), Hb (coefficient&#x02005;=&#x02005;-0.19175), and BMI (coefficient&#x02005;=&#x02005;-0.16474), respectively. The predictors selected by the EN-Cox model were then entered into an unpenalized Cox PH regression model to determine a baseline for comparison during the approximation of the model. The backward elimination stepwise procedure was utilized to reduce the baseline model to a parsimonious one.</p><p> The results of the reduced EN-Cox PH model as well as the hazard ratios (HRs) (95% CI) of death are presented in <xref rid="T2" ref-type="table">Table 2</xref>. The MDHD dataset did not demonstrate any violation of the PH assumption according to the Schoenfeld residuals (all <italic toggle="yes">P</italic> values&#x02005;&#x0003e;&#x02005;0.1). The <italic toggle="yes">P</italic> value of the global analysis to test the PH assumption was 0.766. Hence, it was possible to use the analysis of the EN-Cox PH model (<xref rid="T2" ref-type="table">Table 2</xref>). Moreover, the graphical evaluation of the fit of the EN-Cox model using Cox-Snell residuals is shown in Figure S2 and confirms its good performance.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><title>Hazard Ratios (95% CIs) for Time to Death in Adult Male Diabetic Hemodialysis Patients Using the Univariate and Reduced Penalized Elastic Net Cox-Adjusted Regression Model
</title></caption><table frame="hsides" rules="none"><tbody><tr><td rowspan="2" colspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;">
<bold>Factors</bold>
</td><td colspan="2" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Univariable Cox regression</bold>
</td><td colspan="3" style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1">
<bold>Multiple Elastic Net Cox Regression </bold>
</td></tr><tr><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>HR (95% CI)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold> Value</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>HR (95% CI)</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold> Value</bold>
</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0.5pt 0pt;border-style: solid none solid none;" rowspan="1" colspan="1">
<bold>PH Assumption Test*</bold>
</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" colspan="1">BMI (kg/m<sup>2</sup>)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02005;&#x02265;&#x02005;25</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">-</td><td style="text-align:center;vertical-align:middle;border-width:0.5pt 0pt 0pt 0pt;border-style: solid none none none;" rowspan="1" colspan="1">&#x02014;</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;25</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.10 (1.24&#x02012;3.79)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.006</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.75 (1.53&#x02012;4.96)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.239</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">UF (mL/kg/h) per one-unit increase</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.75 (0.54&#x02012;0.99)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.044</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.75 (0.57&#x02012;1.02)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.067</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.178</td></tr><tr style="background-color:#e3e8e1"><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Dialysis length (h)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x02265;&#x02005;4</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.50 (0.96&#x02012;2.32)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.072</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.95 (1.77&#x02012;4.88)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.589</td></tr><tr><td rowspan="2" style="text-align:left;vertical-align:middle;" colspan="1">Vascular access</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">AVF</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">CVC</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.80 (1.08&#x02012;2.99)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.024</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.60 (1.51&#x02012;4.60)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;0.001</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.675</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">SBP (mm Hg) per one-unit decrease</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.02 (1.01&#x02012;1.03)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.046</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.02 (1.01&#x02012;1.03)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.003</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.478</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">Potassium (mEq/L) per one-unit increase</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.25 (0.92&#x02012;1.68)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.150</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.35 (0.99&#x02012;1.81)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.059</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.253</td></tr><tr style="background-color:#e3e8e1"><td rowspan="3" style="text-align:left;vertical-align:middle;" colspan="1">Hemoglobin (g/dL)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003e;&#x02005;12.5</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1 (Reference)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02014;</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">11-12.5</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.60 (0.99&#x02012;6.83)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.052</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.99 (1.13&#x02012;7.93)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.028</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.643</td></tr><tr style="background-color:#e3e8e1"><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">&#x02005;&#x0003c;&#x02005;11</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.90 (1.15&#x02012;7.16)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.024</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">2.95 (1.18&#x02012;7.56)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.021</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.634</td></tr><tr><td colspan="2" style="text-align:left;vertical-align:middle;" rowspan="1">LDL (mg/dL) per one-unit increase</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.002 (0.99&#x02012;1.006)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.236</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">1.003 (0.99&#x02012;1.007)</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.165</td><td style="text-align:center;vertical-align:middle;" rowspan="1" colspan="1">0.312</td></tr><tr style="background-color:#e3e8e1"><td colspan="2" style="text-align:left;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1">HDL-C (mg/dL) per one-unit decrease</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">1.02 (0.99&#x02012;1.04)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.110</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">1.02 (1.01&#x02012;1.05)</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.022</td><td style="text-align:center;vertical-align:middle;border-width:0pt 0pt 0.5pt 0pt;border-style: none none solid none;" rowspan="1" colspan="1">0.731</td></tr></tbody></table><table-wrap-foot><fn><p> AVF, Arteriovenous fistula; BMI, Body mass index; CI, Confidence interval; CVC, Central venous catheter; df, Degree of freedom; HDL-C, High-density lipoprotein cholesterol; HR, Hazard ratio; LDL, Low-density lipoprotein; SBP, Systolic blood pressure; UF, Ultrafiltration volume.</p><p>
<italic toggle="yes">Notes:</italic> The <italic toggle="yes">P</italic> value of&#x02005;&#x02264;&#x02005;0.05 is considered significant.</p><p> *<italic toggle="yes">P</italic> value to test the proportional hazards (PH) assumption based on Schoenfeld residuals. The <italic toggle="yes">P</italic> value for global test to check the PH assumption is equal to 0.827 (chi-squared statistic&#x02005;=&#x02005;6.45, df&#x02005;=&#x02005;10). Therefore, the PH assumption held for all covariates in the multiple Cox-adjusted elastic net regression model.</p></fn></table-wrap-foot></table-wrap><p> The regression coefficients estimated by the reduced EN-Cox model can be interpreted as the average value of each predictor&#x02019;s effect on the OS rate over time. BMI&#x02005;&#x0003c;&#x02005;25 kg/m<sup>2</sup> (HR&#x02005;=&#x02005;2.75, 95% CI: 1.53&#x02012;4.96, <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001), dialysis duration&#x02005;&#x02265;&#x02005;4 hour/session (HR&#x02005;=&#x02005;2.95, 95% CI: 1.77&#x02012;4.88, <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001), an increase in systolic blood pressure (SBP) (HR&#x02005;=&#x02005;1.02, 95% CI: 1.01&#x02012;1.03, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.003), hemoglobin (Hb) level&#x02005;&#x0003c;&#x02005;11 g/dL (HR&#x02005;=&#x02005;2.95, 95% CI: 1.18&#x02012;7.56, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.021) and 11&#x02005;&#x02264;&#x02005;Hb&#x02005;&#x02264;&#x02005;12.5 g/dL (HR&#x02005;=&#x02005;2.99, 95% CI: 1.13&#x02012;7.93, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.028), and higher levels of serum high-density lipoprotein cholesterol (HDL-C) (HR&#x02005;=&#x02005;1.02, 95% CI: 1.01&#x02012;1.03, <italic toggle="yes">P</italic>&#x02005;=&#x02005;0.022) were associated with lower OS time in the MDHD patients. Furthermore, MDHD patients with AVF had the highest OS rate compared to those who underwent dialysis with central venous catheter (CVC) (HR&#x02005;=&#x02005;2.60, 95% CI: 1.51&#x02012;4.60, <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;0.001) (<xref rid="T2" ref-type="table">Table 2</xref>).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p> To the best of our knowledge, this was the first time that the EN-Cox regression model, as a flexible machine learning approach, was utilized to obtain a sparse regression model for predicting OS in MDHD patients. One of the major advantages of the EN-Cox regression model over the other penalization approaches is that it provides the researcher with a wide range of regression models by varying the regularization parameter (<italic toggle="yes">w</italic>) over the interval [0, 1]. In the present study, the five-fold cross-validation technique was used to select the optimal regularization parameters.</p><p> According to the machine learning analyses in the current study, several risk factors such as duration of dialysis per session, BMI, Hb level, HDL-C, and CVC as vascular access were associated with the OS of the MDHD patients. The UF rate is a function of the amount of fluid removed during each HD session. In general, a higher ultrafiltration rate is associated with worse outcomes such as a shorter survival time and more rapid loss of residual kidney function among ESRD patients receiving HD therapy.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> In addition, better appetite and nutrition conditions as well as higher interdialytic weight gains lead to a higher sodium and water intake (volume overload). This can cause patients to receive a higher UF during HD with a relatively fixed duration to reduce the excess volume.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> It is well documented that rapid fluid removal in each session is linked to higher mortality.<sup><xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref></sup> In contrast to previous studies, it was found in the current study that each unit increase in the UF volume from 1.83 mL/kg/h would decrease the risk of mortality by 25% in the MDHD patients.</p><p> Previous studies have shown that longer HD sessions (&#x02005;&#x02265;&#x02005;3.5&#x02012;4 hours) are associated with a lower mortality rate compared with a referent group receiving less than 3.5&#x02012;4 hours of treatment.<sup><xref rid="R31" ref-type="bibr">31</xref>-<xref rid="R33" ref-type="bibr">33</xref></sup> Similarly, in a large cohort study in the United States, Kim et al reported that the HD patients with a longer dialysis treatment time had significantly more prolonged OS, especially in subgroups with a lower UF rate. It seemed that by increasing the dialysis time, the patients could better tolerate UF, the removal of uremic toxic materials increased, the episodes of intradialytic hypotension were reduced, and the control of blood pressure was improved.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> In contrast to the aforementioned studies, the machine learning analysis in the present study indicated that the session lengths of&#x02005;&#x02265;&#x02005;4 hours were associated with a significantly higher mortality rate (almost 3-fold) compared with a referent group receiving&#x02005;&#x0003c;&#x02005;4-hour treatments. Several possible reasons can explain this finding. Most previous researches have studied the association between mortality and dialysis session length independent of the dialysis adequacy indices such as Kt/V<sub>urea</sub>. These studies were beset by methodological shortcomings which may have led to biased results.<sup><xref rid="R33" ref-type="bibr">33</xref>-<xref rid="R35" ref-type="bibr">35</xref></sup> According to the penalized elastic net regression model in the current study, Kt/V<sub>urea</sub> was not selected as an important risk factor for death among the MDHD patients. Therefore, it was not included in the final model for adjustment. In addition, about 30% of cases with longer session lengths (&#x02265;&#x02005;240 minutes) did not achieve adequate dialysis (i.e. their Kt/V<sub>urea</sub> was&#x02005;&#x0003c;&#x02005;1.2). More importantly, changes in session length over time can influence the association between the mortality rate and the dialysis session length. For instance, in a national cohort of HD patients, Brunelli et alused a marginal structural analysis to adjust the time-dependent confounding association between the session length and mortality.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> It has been shown that causal inference in epidemiology with time-dependent covariates in conventional statistical adjustment approaches can lead to biased estimates of the causal association.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> Hence, it seems that the HD session length should have been entered into the elastic net Cox model as a time-dependent feature in the current study. Moreover, it should be noted that, unlike other studies, not only a new machine learning approach was used in the current study but also a specific HD population (MDHD patients) was included for analysis. In addition, while previous studies using conventional methods considered session length as a baseline value,<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> the average of the repeated measures of HD session lengths in the analyses was used in the current study in order to reduce bias in the parameter estimates.</p><p> According to the literature, HD patients with higher BMI had a more prolonged OS. This may be due to the effects of higher BMI on decreasing HD patients&#x02019; cytokines and neurohormones. In addition, these patients have better hemodynamic status.<sup><xref rid="R38" ref-type="bibr">38</xref>-<xref rid="R40" ref-type="bibr">40</xref></sup> Moreover, the machine learning analyses of the current study demonstrated that the risk of death for MDHD patients with BMI&#x02005;&#x0003c;&#x02005;25 kg/m<sup>2</sup> was 2.75 times higher than for those with BMI&#x02005;&#x0003e;&#x02005;25 kg/m<sup>2</sup>. Although high BMI is a potential risk factor for ESRD, weight loss in patients undergoing dialysis is not recommended.<sup><xref rid="R41" ref-type="bibr">41</xref></sup> Furthermore, it is worth mentioning that a high fat tissue index and a high skeletal muscle mass are more predictive than BMI and are independently associated with reduced risks of all-cause mortality in dialysis patients.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Two main reasons have been suggested in this regard. First, malnutrition is very common in patients undergoing HD and is a main predictor of mortality. Second, a high BMI level is strongly associated with a higher survival rate in HD patients.<sup><xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup></p><p> With the initial vascular access type, the HD process can usually be performed using the two methods of AVF and CVC.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Although the risk of infection is higher in CVC, in most cases, dialysis must unavoidably be initiated with it.<sup><xref rid="R44" ref-type="bibr">44</xref>,<xref rid="R45" ref-type="bibr">45</xref></sup> Our findings revealed that using CVC as the initial vascular access increased the risk of death about 2.6 times compared with AVF. In line with the current study, a systematic review showed that the risk for all-cause mortality due to using CVC as vascular access in HD patients was 1.5 times higher than that of AVF users.<sup><xref rid="R46" ref-type="bibr">46</xref></sup> However, a substantial difference in the death rate was observed based on the initial type of vascular access (CVC or AVF). The lowest mortality rate was reported among those with AVF as the initial vascular access.<sup><xref rid="R47" ref-type="bibr">47</xref>,<xref rid="R48" ref-type="bibr">48</xref></sup></p><p> Erythropoietin deficiency (due to a disruption in renal erythropoietin-producing cells) in ESRD leads to anemia which is associated with several morbidities, CKD progression, and higher all-cause mortality.<sup><xref rid="R49" ref-type="bibr">49</xref>,<xref rid="R50" ref-type="bibr">50</xref></sup> A multicenter study showed that a serum Hb level of 11&#x02012;25 g/dL could prolong OS in patients undergoing HD.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Similarly, the findings of the current research revealed that the risk of death in MDHD patients with a serum Hb level of&#x02005;&#x0003c;&#x02005;12.5 g/dL was almost three times higher than that of other patients. It should be noted that intensive treatment of anemia especially with erythropoietin-stimulating agents to target the serum Hb levels of&#x02005;&#x0003e;&#x02005;12 g/dL may disrupt cardiovascular safety.<sup><xref rid="R49" ref-type="bibr">49</xref></sup> Furthermore, high levels of ferritin and hyperkalemia due to the administration of RBC could increase the risk of infection, hospitalization, and cardiovascular events.<sup><xref rid="R13" ref-type="bibr">13</xref></sup></p><p> Our results indicated that the concentration of serum potassium tended to decrease the OS of the MDHD patients since it increased the probability of death by about 35% with a one-unit increase in its amount from 5.5 mEq/L (the threshold of hyperkalemia). Moreover, it has been well documented that hyperkalemia and hypokalemia are both potentially life-threatening conditions, especially in dialysis patients, and should be corrected immediately to prevent cardiovascular events.<sup><xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref></sup> Previous researches have demonstrated that while serum potassium values&#x02005;&#x0003c;&#x02005;4.0 or&#x02005;&#x0003e;&#x02005;5.7 mEq/L shorten the OS of HD patients, serum potassium value of 4.6&#x02012;5.3 mEq/L increases it.<sup><xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R53" ref-type="bibr">53</xref></sup> In addition, it should be noted that the longer the interdialytic interval (more than 48 hours), the greater the odds of hyperkalemia which itself is associated with the mortality of MDHD patients.<sup><xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup> Although the regulation of serum potassium levels is very important, there is controversy about the concentration of dialysate potassium.<sup><xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R55" ref-type="bibr">55</xref></sup></p><p> The level of serum HDL-C, which is inversely associated with plaque formation and the accelerated progression of atherogenesis, is reduced in dialysis patients.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R56" ref-type="bibr">56</xref>-<xref rid="R58" ref-type="bibr">58</xref></sup> Our findings also revealed that the risk of mortality is reduced by 20% per one-unit increase in the level of serum HDL-C. Moradi et alfound a U-shaped relationship between HDL-C and mortality in HD patients. Their analyses demonstrated that the serum HDL-C concentrations from 50 to&#x02005;&#x0003c;&#x02005;60 mg/dL were beneficial for OS in HD patients.<sup><xref rid="R57" ref-type="bibr">57</xref></sup> However, no successful therapeutic strategy to increase HDL-C or to reduce the progression of CKD has been presented.<sup><xref rid="R58" ref-type="bibr">58</xref></sup></p><p> The duration of the patients&#x02019; follow-up was approximately 8 years (&#x02005;&#x0003e;&#x02005;2803 days) which was another strength of the machine learning analysis in this study. The other strong points of the current research were the substantial number of patients, using HD session indices, and employing epidemiological, clinical, and laboratory factors. A weakness of the present research was that the cause of death was not recorded in the SUMS database. Moreover, it should be mentioned that since diabetic HD patients receive proper medical health care, our results can be confounded.</p></sec><sec sec-type="conclusion" id="s5"><title>Conclusion</title><p> Our findings revealed that a longer dialysis duration in each session (&#x02005;&#x0003e;&#x02005;4 hours), anemia (serum Hb level&#x02005;&#x0003c;&#x02005;12.5 g/dL), CVC as vascular access, decrease in BMI&#x02005;&#x0003c;&#x02005;25 kg/m<sup>2</sup> and lower HDL-C levels could shorten the OS of MDHD patients. Also, each unit reduction in SBP increased the risk of OS by 2%. Hence, it is suggested that these factors should be modified for better survival of MDHD patients and that more attention should be paid to measuring these factors in the laboratories. The EN-Cox model used in the current study provides a new insight into using the machine learning algorithm for investigating the determinants of OS in time-to-event data. Compared with conventional survival time approaches, the EN-Cox model allows researchers to include several highly correlated factors in the regression model simultaneously. Hence, it is recommended that the EN-Cox regression model is used for survival analysis in multicollinearity cases, especially when the sample size is extremely small. In addition, when the OEPCC are too few, the EN-Cox regression model can produce stable and reliable results.</p></sec><sec sec-type="supplementary-material" id="Suppl"><title>Supplementary Files
</title><supplementary-material id="Suppl1" position="float" content-type="local-data"><caption><p>Supplementary file 1 contains Table S1 and Figures S1 and S2.
</p></caption><media xlink:href="aim-28-9-s001.pdf"/></supplementary-material><supplementary-material id="Suppl2" position="float" content-type="local-data"><caption><p>Supplementary file 2 contains EN-Cox model theory.
</p></caption><media xlink:href="aim-28-9-s002.pdf"/></supplementary-material></sec></body><back><ack><p> The authors would like to thank the members of the Shiraz University of Medical Sciences (SUMS) Specific Diseases Department, especially Dr. Mohammad Reza Morvaridi, for his cooperation and patience in supporting data collection.</p></ack><fn-group><fn id="n1" fn-type="COI-statement"><p>
<bold>Competing Interests</bold>
</p><p> The authors declared that they have no conflict of interest.</p></fn><fn id="n2" fn-type="other"><p>
<bold>Data Availability Statement</bold>
</p><p> The data are available on logical request.</p></fn><fn id="n3" fn-type="other"><p>
<bold>Ethical Approval</bold>
</p><p> This study was approved by the Vice-Chancellor of Research and Technology (Grant No.:22864), as well as the Ethics Committee of Shiraz University of Medical Sciences (IR.sums.med.rec.1400.11).</p></fn><fn id="n4" fn-type="financial-disclosure"><p>
<bold>Funding</bold>
</p><p> Shiraz University of Medical Sciences (Grant No. 22864).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossing</surname><given-names>K</given-names></name>
<name><surname>Christensen</surname><given-names>PK</given-names></name>
<name><surname>Hovind</surname><given-names>P</given-names></name>
<name><surname>Tarnow</surname><given-names>L</given-names></name>
<name><surname>Rossing</surname><given-names>P</given-names></name>
<name><surname>Parving</surname><given-names>HH</given-names></name>
</person-group><article-title>Progression of nephropathy in type 2 diabetic patients</article-title><source>Kidney Int</source><year>2004</year><volume>66</volume><issue>4</issue><fpage>1596</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00925.x</pub-id><pub-id pub-id-type="pmid">15458456</pub-id>
</element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ezzatzadegan Jahromi</surname><given-names>S</given-names></name>
<name><surname>Haghighi</surname><given-names>G</given-names></name>
<name><surname>Roozbeh</surname><given-names>J</given-names></name>
<name><surname>Ebrahimi</surname><given-names>V</given-names></name>
</person-group><article-title>Comparisons between different blood pressure measurement techniques in patients with chronic kidney disease</article-title><source>Kidney Res Clin Pract</source><year>2019</year><volume>38</volume><issue>2</issue><fpage>212</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.23876/j.krcp.18.0109</pub-id><pub-id pub-id-type="pmid">30970391</pub-id>
</element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erkol Tuncer</surname><given-names>GH</given-names></name>
<name><surname>Ekim</surname><given-names>M</given-names></name>
<name><surname>Okulu</surname><given-names>E</given-names></name>
<name><surname>Atasay</surname><given-names>B</given-names></name>
<name><surname>Kendirli</surname><given-names>T</given-names></name>
</person-group><article-title>Continuous renal replacement therapy in critically ill children: single-center experience</article-title><source>Turk J Med Sci</source><year>2021</year><volume>51</volume><issue>1</issue><fpage>188</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.3906/sag-2006-227</pub-id><pub-id pub-id-type="pmid">33172226</pub-id>
</element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ezzatzadegan Jahromi</surname><given-names>S</given-names></name>
<name><surname>Ahmed</surname><given-names>F</given-names></name>
<name><surname>Pourahmad</surname><given-names>S</given-names></name>
<name><surname>Roozbeh</surname><given-names>J</given-names></name>
<name><surname>Najafi</surname><given-names>I</given-names></name>
<name><surname>Ebrahimi</surname><given-names>V</given-names></name>
</person-group><article-title>Predictors of peritoneal dialysis associated peritonitis; application of the zero-inflated negative binomial model</article-title><source>J Nephropathol</source><year>2019</year><volume>8</volume><issue>4</issue><fpage>e36</fpage><pub-id pub-id-type="doi">10.15171/jnp.2019.36</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Najafi</surname><given-names>F</given-names></name>
<name><surname>Mousavi-Roknabadi</surname><given-names>RS</given-names></name>
<name><surname>Pirdehghan</surname><given-names>A</given-names></name>
<name><surname>Rahimian</surname><given-names>M</given-names></name>
<name><surname>Nourimajalan</surname><given-names>N</given-names></name>
</person-group><article-title>Effect of N-acetylcysteine on hsCRP in patients on continues ambulatory peritoneal dialysis: a quasi-experimental study</article-title><source>Nephrourol Mon</source><year>2021</year><volume>13</volume><issue>3</issue><fpage>e113990</fpage><pub-id pub-id-type="doi">10.5812/numonthly.113990</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mousavi-Roknabadi</surname><given-names>RS</given-names></name>
<name><surname>Ershadi</surname><given-names>F</given-names></name>
<name><surname>Hadi</surname><given-names>N</given-names></name>
<name><surname>Roozbeh Shahroodi</surname><given-names>J</given-names></name>
<name><surname>Shayan</surname><given-names>Z</given-names></name>
<name><surname>Keshavarz</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Effect of renal transplantation on health-related quality of life in patients with end-stage renal disease; a quasi-experimental study</article-title><source>Nephrourol Mon</source><year>2019</year><volume>11</volume><issue>2</issue><fpage>e79497</fpage><pub-id pub-id-type="doi">10.5812/numonthly.79497</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>B&#x00130;rg&#x00130;</surname><given-names>E</given-names></name>
<name><surname>Durmaz</surname><given-names>H</given-names></name>
</person-group><article-title>Placement of hemodialysis catheters with the help of the micropuncture technique in patients with central venous occlusion and limited access</article-title><source>Turk J Med Sci</source><year>2021</year><volume>51</volume><issue>1</issue><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.3906/sag-2006-11</pub-id><pub-id pub-id-type="pmid">32892538</pub-id>
</element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sipahi</surname><given-names>S</given-names></name>
<name><surname>Dheir</surname><given-names>H</given-names></name>
<name><surname>To&#x000e7;o&#x0011f;lu</surname><given-names>A</given-names></name>
<name><surname>Bekta&#x0015f;</surname><given-names>M</given-names></name>
<name><surname>A&#x000e7;&#x00131;kg&#x000f6;z</surname><given-names>SB</given-names></name>
<name><surname>Gen&#x000e7;</surname><given-names>AC</given-names></name>
<etal/>
</person-group><article-title>Characteristics and mortality determinants of COVID-19 patients undergoing hemodialysis</article-title><source>Turk J Med Sci</source><year>2021</year><volume>51</volume><issue>2</issue><fpage>421</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.3906/sag-2006-54</pub-id><pub-id pub-id-type="pmid">32950045</pub-id>
</element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Triebswetter</surname><given-names>S</given-names></name>
<name><surname>Gutjahr-Lengsfeld</surname><given-names>LJ</given-names></name>
<name><surname>Schmidt</surname><given-names>KR</given-names></name>
<name><surname>Drechsler</surname><given-names>C</given-names></name>
<name><surname>Wanner</surname><given-names>C</given-names></name>
<name><surname>Krane</surname><given-names>V</given-names></name>
</person-group><article-title>Long-term survivor characteristics in hemodialysis patients with type 2 diabetes</article-title><source>Am J Nephrol</source><year>2018</year><volume>47</volume><issue>1</issue><fpage>30</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000485842</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yajima</surname><given-names>T</given-names></name>
<name><surname>Arao</surname><given-names>M</given-names></name>
<name><surname>Yajima</surname><given-names>K</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
<name><surname>Yasuda</surname><given-names>K</given-names></name>
</person-group><article-title>The associations of fat tissue and muscle mass indices with all-cause mortality in patients undergoing hemodialysis</article-title><source>PLoS One</source><year>2019</year><volume>14</volume><issue>2</issue><fpage>e0211988</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0211988</pub-id><pub-id pub-id-type="pmid">30759133</pub-id>
</element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marcelli</surname><given-names>D</given-names></name>
<name><surname>Spotti</surname><given-names>D</given-names></name>
<name><surname>Conte</surname><given-names>F</given-names></name>
<name><surname>Tagliaferro</surname><given-names>A</given-names></name>
<name><surname>Limido</surname><given-names>A</given-names></name>
<name><surname>Lonati</surname><given-names>F</given-names></name>
<etal/>
</person-group><article-title>Survival of diabetic patients on peritoneal dialysis or hemodialysis</article-title><source>Perit Dial Int</source><year>1996</year><volume>16 Suppl 1</volume><fpage>S283</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8728208</pub-id>
</element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Demirta&#x0015f;</surname><given-names>S</given-names></name>
<name><surname>Nergiso&#x0011f;lu</surname><given-names>G</given-names></name>
<name><surname>Yarpuzlu</surname><given-names>AA</given-names></name>
<name><surname>Karaca</surname><given-names>L</given-names></name>
</person-group><article-title>The relation between low-density lipoprotein (LDL) oxidation and hemodialysis with respect to membrane types protective effects of vitamin E-bonded membrane</article-title><source>Turk J Med Sci</source><year>2002</year><volume>32</volume><issue>2</issue><fpage>93</fpage><lpage>100</lpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuragano</surname><given-names>T</given-names></name>
<name><surname>Matsumura</surname><given-names>O</given-names></name>
<name><surname>Matsuda</surname><given-names>A</given-names></name>
<name><surname>Hara</surname><given-names>T</given-names></name>
<name><surname>Kiyomoto</surname><given-names>H</given-names></name>
<name><surname>Murata</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients</article-title><source>Kidney Int</source><year>2014</year><volume>86</volume><issue>4</issue><fpage>845</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/ki.2014.114</pub-id><pub-id pub-id-type="pmid">24759150</pub-id>
</element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebrahimi</surname><given-names>V</given-names></name>
<name><surname>Khademian</surname><given-names>MH</given-names></name>
<name><surname>Masoumi</surname><given-names>SJ</given-names></name>
<name><surname>Morvaridi</surname><given-names>MR</given-names></name>
<name><surname>Ezzatzadegan Jahromi</surname><given-names>S</given-names></name>
</person-group><article-title>Factors influencing survival time of hemodialysis patients; time to event analysis using parametric models: a cohort study</article-title><source>BMC Nephrol</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>215</fpage><pub-id pub-id-type="doi">10.1186/s12882-019-1382-2</pub-id><pub-id pub-id-type="pmid">31185926</pub-id>
</element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carrero</surname><given-names>JJ</given-names></name>
<name><surname>Hecking</surname><given-names>M</given-names></name>
<name><surname>Chesnaye</surname><given-names>NC</given-names></name>
<name><surname>Jager</surname><given-names>KJ</given-names></name>
</person-group><article-title>Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease</article-title><source>Nat Rev Nephrol</source><year>2018</year><volume>14</volume><issue>3</issue><fpage>151</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2017.181</pub-id><pub-id pub-id-type="pmid">29355169</pub-id>
</element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Villar</surname><given-names>E</given-names></name>
<name><surname>Remontet</surname><given-names>L</given-names></name>
<name><surname>Labeeuw</surname><given-names>M</given-names></name>
<name><surname>Ecochard</surname><given-names>R</given-names></name>
</person-group><article-title>Effect of age, gender, and diabetes on excess death in end-stage renal failure</article-title><source>J Am Soc Nephrol</source><year>2007</year><volume>18</volume><issue>7</issue><fpage>2125</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1681/asn.2006091048</pub-id><pub-id pub-id-type="pmid">17582163</pub-id>
</element-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="other"> Swartling O, Rydell H, Stendahl M, Segelmark M, Trolle Lagerros Y, Evans M. CKD progression and mortality among men and women: a nationwide study in Sweden. Am J Kidney Dis 2021;78(2):190-9.e1. <pub-id pub-id-type="doi">10.1053/j.ajkd.2020.11.026</pub-id>. </mixed-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shayan</surname><given-names>Z</given-names></name>
<name><surname>Ebrahimi</surname><given-names>V</given-names></name>
<name><surname>Ezzatzadegan Jahromi</surname><given-names>S</given-names></name>
</person-group><article-title>Factors associated with short-term and long-term survival in patients undergoing hemodialysis using semi- parametric mixture cure models</article-title><source>Iran J Kidney Dis</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">32156841</pub-id>
</element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>PY</given-names></name>
<name><surname>Chien</surname><given-names>LN</given-names></name>
<name><surname>Lin</surname><given-names>YF</given-names></name>
<name><surname>Wu</surname><given-names>MS</given-names></name>
<name><surname>Chiu</surname><given-names>WT</given-names></name>
<name><surname>Chiou</surname><given-names>HY</given-names></name>
</person-group><article-title>Risk factors of gender for renal progression in patients with early chronic kidney disease</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><issue>30</issue><fpage>e4203</fpage><pub-id pub-id-type="doi">10.1097/md.0000000000004203</pub-id><pub-id pub-id-type="pmid">27472690</pub-id>
</element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peduzzi</surname><given-names>P</given-names></name>
<name><surname>Concato</surname><given-names>J</given-names></name>
<name><surname>Feinstein</surname><given-names>AR</given-names></name>
<name><surname>Holford</surname><given-names>TR</given-names></name>
</person-group><article-title>Importance of events per independent variable in proportional hazards regression analysis II Accuracy and precision of regression estimates</article-title><source>J Clin Epidemiol</source><year>1995</year><volume>48</volume><issue>12</issue><fpage>1503</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(95)00048-8</pub-id><pub-id pub-id-type="pmid">8543964</pub-id>
</element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peduzzi</surname><given-names>P</given-names></name>
<name><surname>Concato</surname><given-names>J</given-names></name>
<name><surname>Kemper</surname><given-names>E</given-names></name>
<name><surname>Holford</surname><given-names>TR</given-names></name>
<name><surname>Feinstein</surname><given-names>AR</given-names></name>
</person-group><article-title>A simulation study of the number of events per variable in logistic regression analysis</article-title><source>J Clin Epidemiol</source><year>1996</year><volume>49</volume><issue>12</issue><fpage>1373</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s0895-4356(96)00236-3</pub-id><pub-id pub-id-type="pmid">8970487</pub-id>
</element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vittinghoff</surname><given-names>E</given-names></name>
<name><surname>McCulloch</surname><given-names>CE</given-names></name>
</person-group><article-title>Relaxing the rule of ten events per variable in logistic and Cox regression</article-title><source>Am J Epidemiol</source><year>2007</year><volume>165</volume><issue>6</issue><fpage>710</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/aje/kwk052</pub-id><pub-id pub-id-type="pmid">17182981</pub-id>
</element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>E</given-names></name>
</person-group><article-title>Multivariate survival analysis using Cox&#x02019;s regression model</article-title><source>Hepatology</source><year>1987</year><volume>7</volume><issue>6</issue><fpage>1346</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1002/hep.1840070628</pub-id><pub-id pub-id-type="pmid">3679094</pub-id>
</element-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="other"> Kleinbaum DG, Klein M. Survival Analysis: A Self&#x02010;Learning Text. New York: Springer-Verlag; 2016. </mixed-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>H</given-names></name>
<name><surname>Hastie</surname><given-names>T</given-names></name>
</person-group><article-title>Regularization and variable selection via the elastic net</article-title><source>J R Stat Soc Series B Stat Methodol</source><year>2005</year><volume>67</volume><issue>2</issue><fpage>301</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/j.1467-9868.2005.00503.x</pub-id></element-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="other"> Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. Springer Science &#x00026; Business Media; 2009. </mixed-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hasegawa</surname><given-names>T</given-names></name>
<name><surname>Misawa</surname><given-names>S</given-names></name>
<name><surname>Nakagawa</surname><given-names>S</given-names></name>
<name><surname>Tanaka</surname><given-names>S</given-names></name>
<name><surname>Tanase</surname><given-names>T</given-names></name>
<name><surname>Ugai</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Restricted mean survival time as a summary measure of time-to-event outcome</article-title><source>Pharm Stat</source><year>2020</year><volume>19</volume><issue>4</issue><fpage>436</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/pst.2004</pub-id><pub-id pub-id-type="pmid">32072769</pub-id>
</element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>YJ</given-names></name>
<name><surname>Okuda</surname><given-names>Y</given-names></name>
<name><surname>Sy</surname><given-names>J</given-names></name>
<name><surname>Lee</surname><given-names>YK</given-names></name>
<name><surname>Obi</surname><given-names>Y</given-names></name>
<name><surname>Cho</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Ultrafiltration rate, residual kidney function, and survival among patients treated with reduced-frequency hemodialysis</article-title><source>Am J Kidney Dis</source><year>2020</year><volume>75</volume><issue>3</issue><fpage>342</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2019.08.019</pub-id><pub-id pub-id-type="pmid">31813665</pub-id>
</element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>TW</given-names></name>
<name><surname>Chang</surname><given-names>TI</given-names></name>
<name><surname>Kim</surname><given-names>TH</given-names></name>
<name><surname>Chou</surname><given-names>JA</given-names></name>
<name><surname>Soohoo</surname><given-names>M</given-names></name>
<name><surname>Ravel</surname><given-names>VA</given-names></name>
<etal/>
</person-group><article-title>Association of ultrafiltration rate with mortality in incident hemodialysis patients</article-title><source>Nephron</source><year>2018</year><volume>139</volume><issue>1</issue><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1159/000486323</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Assimon</surname><given-names>MM</given-names></name>
<name><surname>Wenger</surname><given-names>JB</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Flythe</surname><given-names>JE</given-names></name>
</person-group><article-title>Ultrafiltration rate and mortality in maintenance hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2016</year><volume>68</volume><issue>6</issue><fpage>911</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.06.020</pub-id><pub-id pub-id-type="pmid">27575009</pub-id>
</element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swaminathan</surname><given-names>S</given-names></name>
<name><surname>Mor</surname><given-names>V</given-names></name>
<name><surname>Mehrotra</surname><given-names>R</given-names></name>
<name><surname>Trivedi</surname><given-names>AN</given-names></name>
</person-group><article-title>Initial session duration and mortality among incident hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2017</year><volume>70</volume><issue>1</issue><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2016.11.017</pub-id><pub-id pub-id-type="pmid">28233656</pub-id>
</element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flythe</surname><given-names>JE</given-names></name>
<name><surname>Kimmel</surname><given-names>SE</given-names></name>
<name><surname>Brunelli</surname><given-names>SM</given-names></name>
</person-group><article-title>Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality</article-title><source>Kidney Int</source><year>2011</year><volume>79</volume><issue>2</issue><fpage>250</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/ki.2010.383</pub-id><pub-id pub-id-type="pmid">20927040</pub-id>
</element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>MR</given-names></name>
<name><surname>Byrne</surname><given-names>BG</given-names></name>
<name><surname>Kerr</surname><given-names>PG</given-names></name>
<name><surname>McDonald</surname><given-names>SP</given-names></name>
</person-group><article-title>Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><issue>7</issue><fpage>1229</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000188</pub-id><pub-id pub-id-type="pmid">16609687</pub-id>
</element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saran</surname><given-names>R</given-names></name>
<name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name>
<name><surname>Levin</surname><given-names>NW</given-names></name>
<name><surname>Twardowski</surname><given-names>ZJ</given-names></name>
<name><surname>Wizemann</surname><given-names>V</given-names></name>
<name><surname>Saito</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS</article-title><source>Kidney Int</source><year>2006</year><volume>69</volume><issue>7</issue><fpage>1222</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5000186</pub-id><pub-id pub-id-type="pmid">16609686</pub-id>
</element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lowrie</surname><given-names>EG</given-names></name>
<name><surname>Li</surname><given-names>Z</given-names></name>
<name><surname>Ofsthun</surname><given-names>N</given-names></name>
<name><surname>Lazarus</surname><given-names>JM</given-names></name>
</person-group><article-title>Measurement of dialyzer clearance, dialysis time, and body size: death risk relationships among patients</article-title><source>Kidney Int</source><year>2004</year><volume>66</volume><issue>5</issue><fpage>2077</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00987.x</pub-id><pub-id pub-id-type="pmid">15496182</pub-id>
</element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brunelli</surname><given-names>SM</given-names></name>
<name><surname>Chertow</surname><given-names>GM</given-names></name>
<name><surname>Ankers</surname><given-names>ED</given-names></name>
<name><surname>Lowrie</surname><given-names>EG</given-names></name>
<name><surname>Thadhani</surname><given-names>R</given-names></name>
</person-group><article-title>Shorter dialysis times are associated with higher mortality among incident hemodialysis patients</article-title><source>Kidney Int</source><year>2010</year><volume>77</volume><issue>7</issue><fpage>630</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/ki.2009.523</pub-id><pub-id pub-id-type="pmid">20090666</pub-id>
</element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robins</surname><given-names>JM</given-names></name>
<name><surname>Hern&#x000e1;n</surname><given-names>MA</given-names></name>
<name><surname>Brumback</surname><given-names>B</given-names></name>
</person-group><article-title>Marginal structural models and causal inference in epidemiology</article-title><source>Epidemiology</source><year>2000</year><volume>11</volume><issue>5</issue><fpage>550</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1097/00001648-200009000-00011</pub-id><pub-id pub-id-type="pmid">10955408</pub-id>
</element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jialin</surname><given-names>W</given-names></name>
<name><surname>Yi</surname><given-names>Z</given-names></name>
<name><surname>Weijie</surname><given-names>Y</given-names></name>
</person-group><article-title>Relationship between body mass index and mortality in hemodialysis patients: a meta-analysis</article-title><source>Nephron Clin Pract</source><year>2012</year><volume>121</volume><issue>3-4</issue><fpage>c102</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1159/000345159</pub-id><pub-id pub-id-type="pmid">23182883</pub-id>
</element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>J</given-names></name>
<name><surname>Jin</surname><given-names>DC</given-names></name>
<name><surname>Molnar</surname><given-names>MZ</given-names></name>
<name><surname>Dukkipati</surname><given-names>R</given-names></name>
<name><surname>Kim</surname><given-names>YL</given-names></name>
<name><surname>Jing</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Mortality predictability of body size and muscle mass surrogates in Asian vs white and African American hemodialysis patients</article-title><source>Mayo Clin Proc</source><year>2013</year><volume>88</volume><issue>5</issue><fpage>479</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2013.01.025</pub-id><pub-id pub-id-type="pmid">23562348</pub-id>
</element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mafra</surname><given-names>D</given-names></name>
<name><surname>Farage</surname><given-names>NE</given-names></name>
<name><surname>Azevedo</surname><given-names>DL</given-names></name>
<name><surname>Viana</surname><given-names>GG</given-names></name>
<name><surname>Mattos</surname><given-names>JP</given-names></name>
<name><surname>Velarde</surname><given-names>LG</given-names></name>
<etal/>
</person-group><article-title>Impact of serum albumin and body-mass index on survival in hemodialysis patients</article-title><source>Int Urol Nephrol</source><year>2007</year><volume>39</volume><issue>2</issue><fpage>619</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s11255-007-9201-2</pub-id><pub-id pub-id-type="pmid">17450420</pub-id>
</element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Badve</surname><given-names>SV</given-names></name>
<name><surname>Paul</surname><given-names>SK</given-names></name>
<name><surname>Klein</surname><given-names>K</given-names></name>
<name><surname>Clayton</surname><given-names>PA</given-names></name>
<name><surname>Hawley</surname><given-names>CM</given-names></name>
<name><surname>Brown</surname><given-names>FG</given-names></name>
<etal/>
</person-group><article-title>The association between body mass index and mortality in incident dialysis patients</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>12</issue><fpage>e114897</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0114897</pub-id><pub-id pub-id-type="pmid">25513810</pub-id>
</element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name>
<name><surname>Kopple</surname><given-names>JD</given-names></name>
<name><surname>Block</surname><given-names>G</given-names></name>
<name><surname>Humphreys</surname><given-names>MH</given-names></name>
</person-group><article-title>A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients</article-title><source>Am J Kidney Dis</source><year>2001</year><volume>38</volume><issue>6</issue><fpage>1251</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2001.29222</pub-id><pub-id pub-id-type="pmid">11728958</pub-id>
</element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abbott</surname><given-names>KC</given-names></name>
<name><surname>Glanton</surname><given-names>CW</given-names></name>
<name><surname>Trespalacios</surname><given-names>FC</given-names></name>
<name><surname>Oliver</surname><given-names>DK</given-names></name>
<name><surname>Ortiz</surname><given-names>MI</given-names></name>
<name><surname>Agodoa</surname><given-names>LY</given-names></name>
<etal/>
</person-group><article-title>Body mass index, dialysis modality, and survival: analysis of the United States renal data system dialysis morbidity and mortality wave II study</article-title><source>Kidney Int</source><year>2004</year><volume>65</volume><issue>2</issue><fpage>597</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00385.x</pub-id><pub-id pub-id-type="pmid">14717930</pub-id>
</element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>DH</given-names></name>
<name><surname>Park</surname><given-names>JI</given-names></name>
<name><surname>Lee</surname><given-names>JP</given-names></name>
<name><surname>Kim</surname><given-names>YL</given-names></name>
<name><surname>Kang</surname><given-names>SW</given-names></name>
<name><surname>Yang</surname><given-names>CW</given-names></name>
<etal/>
</person-group><article-title>The effects of vascular access types on the survival and quality of life and depression in the incident hemodialysis patients</article-title><source>Ren Fail</source><year>2020</year><volume>42</volume><issue>1</issue><fpage>30</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1080/0886022x.2019.1702558</pub-id><pub-id pub-id-type="pmid">31847666</pub-id>
</element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebrahimi</surname><given-names>V</given-names></name>
<name><surname>Sharifi</surname><given-names>M</given-names></name>
<name><surname>Khademian</surname><given-names>MH</given-names></name>
<name><surname>Jafari</surname><given-names>P</given-names></name>
<name><surname>Ezzatzadegan Jahromi</surname><given-names>S</given-names></name>
<name><surname>Sabouri</surname><given-names>S</given-names></name>
</person-group><article-title>Prognosis and long-term overall survival in hypertensive patients undergoing chronic hemodialysis: a multicenter parametric mixture split-population analysis</article-title><source>Arch Iran Med</source><year>2021</year><volume>24</volume><issue>11</issue><fpage>828</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.34172/aim.2021.123</pub-id><pub-id pub-id-type="pmid">34841828</pub-id>
</element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ravani</surname><given-names>P</given-names></name>
<name><surname>Palmer</surname><given-names>SC</given-names></name>
<name><surname>Oliver</surname><given-names>MJ</given-names></name>
<name><surname>Quinn</surname><given-names>RR</given-names></name>
<name><surname>MacRae</surname><given-names>JM</given-names></name>
<name><surname>Tai</surname><given-names>DJ</given-names></name>
<etal/>
</person-group><article-title>Associations between hemodialysis access type and clinical outcomes: a systematic review</article-title><source>J Am Soc Nephrol</source><year>2013</year><volume>24</volume><issue>3</issue><fpage>465</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1681/asn.2012070643</pub-id><pub-id pub-id-type="pmid">23431075</pub-id>
</element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>do Sameiro-Faria</surname><given-names>M</given-names></name>
<name><surname>Ribeiro</surname><given-names>S</given-names></name>
<name><surname>Costa</surname><given-names>E</given-names></name>
<name><surname>Mendon&#x000e7;a</surname><given-names>D</given-names></name>
<name><surname>Teixeira</surname><given-names>L</given-names></name>
<name><surname>Rocha-Pereira</surname><given-names>P</given-names></name>
<etal/>
</person-group><article-title>Risk factors for mortality in hemodialysis patients: two-year follow-up study</article-title><source>Dis Markers</source><year>2013</year><volume>35</volume><issue>6</issue><fpage>791</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2013/518945</pub-id><pub-id pub-id-type="pmid">24347799</pub-id>
</element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Sousa-Martins</surname><given-names>P</given-names></name>
<name><surname>Moura</surname><given-names>A</given-names></name>
<name><surname>Madureira</surname><given-names>J</given-names></name>
<name><surname>Alija</surname><given-names>P</given-names></name>
<name><surname>Oliveira</surname><given-names>JG</given-names></name>
<name><surname>Lopez</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Risk factors for mortality in end-stage kidney disease patients under online-hemodiafiltration: three-year follow-up study</article-title><source>Biomarkers</source><year>2016</year><volume>21</volume><issue>6</issue><fpage>544</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.3109/1354750x.2016.1160428</pub-id><pub-id pub-id-type="pmid">27028295</pub-id>
</element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toft</surname><given-names>G</given-names></name>
<name><surname>Heide-J&#x000f8;rgensen</surname><given-names>U</given-names></name>
<name><surname>van Haalen</surname><given-names>H</given-names></name>
<name><surname>James</surname><given-names>G</given-names></name>
<name><surname>Hedman</surname><given-names>K</given-names></name>
<name><surname>Birn</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study</article-title><source>J Nephrol</source><year>2020</year><volume>33</volume><issue>1</issue><fpage>147</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s40620-019-00652-9</pub-id><pub-id pub-id-type="pmid">31587136</pub-id>
</element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name>
<name><surname>Aronoff</surname><given-names>GR</given-names></name>
</person-group><article-title>Hemoglobin variability in anemia of chronic kidney disease</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><issue>3</issue><fpage>479</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1681/asn.2007070728</pub-id><pub-id pub-id-type="pmid">19211716</pub-id>
</element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yusuf</surname><given-names>AA</given-names></name>
<name><surname>Hu</surname><given-names>Y</given-names></name>
<name><surname>Singh</surname><given-names>B</given-names></name>
<name><surname>Menoyo</surname><given-names>JA</given-names></name>
<name><surname>Wetmore</surname><given-names>JB</given-names></name>
</person-group><article-title>Serum potassium levels and mortality in hemodialysis patients: a retrospective cohort study</article-title><source>Am J Nephrol</source><year>2016</year><volume>44</volume><issue>3</issue><fpage>179</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1159/000448341</pub-id><pub-id pub-id-type="pmid">27592170</pub-id>
</element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrey</surname><given-names>A</given-names></name>
<name><surname>You</surname><given-names>AS</given-names></name>
<name><surname>Kovesdy</surname><given-names>CP</given-names></name>
<name><surname>Nakata</surname><given-names>T</given-names></name>
<name><surname>Veliz</surname><given-names>M</given-names></name>
<name><surname>Nguyen</surname><given-names>DV</given-names></name>
<etal/>
</person-group><article-title>Dialysate potassium and mortality in a prospective hemodialysis cohort</article-title><source>Am J Nephrol</source><year>2018</year><volume>47</volume><issue>6</issue><fpage>415</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1159/000489961</pub-id><pub-id pub-id-type="pmid">29879714</pub-id>
</element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kovesdy</surname><given-names>CP</given-names></name>
<name><surname>Regidor</surname><given-names>DL</given-names></name>
<name><surname>Mehrotra</surname><given-names>R</given-names></name>
<name><surname>Jing</surname><given-names>J</given-names></name>
<name><surname>McAllister</surname><given-names>CJ</given-names></name>
<name><surname>Greenland</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Serum and dialysate potassium concentrations and survival in hemodialysis patients</article-title><source>Clin J Am Soc Nephrol</source><year>2007</year><volume>2</volume><issue>5</issue><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.2215/cjn.04451206</pub-id><pub-id pub-id-type="pmid">17702709</pub-id>
</element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foley</surname><given-names>RN</given-names></name>
<name><surname>Gilbertson</surname><given-names>DT</given-names></name>
<name><surname>Murray</surname><given-names>T</given-names></name>
<name><surname>Collins</surname><given-names>AJ</given-names></name>
</person-group><article-title>Long interdialytic interval and mortality among patients receiving hemodialysis</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>12</issue><fpage>1099</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103313</pub-id><pub-id pub-id-type="pmid">21992122</pub-id>
</element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrey</surname><given-names>A</given-names></name>
<name><surname>You</surname><given-names>AS</given-names></name>
<name><surname>Kovesdy</surname><given-names>CP</given-names></name>
<name><surname>Nakata</surname><given-names>T</given-names></name>
<name><surname>Veliz</surname><given-names>M</given-names></name>
<name><surname>Nguyen</surname><given-names>DV</given-names></name>
<etal/>
</person-group><article-title>Dialysate potassium and mortality in a prospective hemodialysis cohort</article-title><source>Am J Nephrol</source><year>2018</year><volume>47</volume><issue>6</issue><fpage>415</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1159/000489961</pub-id><pub-id pub-id-type="pmid">29879714</pub-id>
</element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nicholls</surname><given-names>SJ</given-names></name>
<name><surname>Nelson</surname><given-names>AJ</given-names></name>
</person-group><article-title>HDL and cardiovascular disease</article-title><source>Pathology</source><year>2019</year><volume>51</volume><issue>2</issue><fpage>142</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.pathol.2018.10.017</pub-id><pub-id pub-id-type="pmid">30612759</pub-id>
</element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moradi</surname><given-names>H</given-names></name>
<name><surname>Streja</surname><given-names>E</given-names></name>
<name><surname>Kashyap</surname><given-names>ML</given-names></name>
<name><surname>Vaziri</surname><given-names>ND</given-names></name>
<name><surname>Fonarow</surname><given-names>GC</given-names></name>
<name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name>
</person-group><article-title>Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2014</year><volume>29</volume><issue>8</issue><fpage>1554</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfu022</pub-id><pub-id pub-id-type="pmid">24574544</pub-id>
</element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rysz</surname><given-names>J</given-names></name>
<name><surname>Gluba-Brz&#x000f3;zka</surname><given-names>A</given-names></name>
<name><surname>Rysz-G&#x000f3;rzy&#x00144;ska</surname><given-names>M</given-names></name>
<name><surname>Franczyk</surname><given-names>B</given-names></name>
</person-group><article-title>The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>601</fpage><pub-id pub-id-type="doi">10.3390/ijms21020601</pub-id><pub-id pub-id-type="pmid">31963445</pub-id>
</element-citation></ref></ref-list></back></article>